PRPaola Rosetti

Paola Rosetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paola Rosetti has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

    by Paola Ulivi, Laura Capelli, Martina Valgiusti, Wainer Zoli, Emanuela Scarpi, Elisa Chiadini, Paola Rosetti, Sara Bravaccini, Daniele Calistri, Luca Saragoni, et al.

    Background: KRASmutations negatively affect outcome after treatment with cetuximab in metastatic colorectal cancer (mCRC) patients. As only 20% ofKRASwild type (WT) patients respond to cetuximab it is possible that other mutations, constitutively activating the EGFR pathway, are present in the non-respondingKRASWT patients. We retrospectively analyzed objective tumor response rate, (ORR) progression-free (PFS) and overall survival (OS) with respect to the mutational status ofKRAS,BRAF,PIK3CAand PTEN expression in mCRC patients treated with a cetuximab-based regimen.Methods: 67 mCRC patients were enrolled onto the study. DNA was extracted from paraffin-embedded sections derived from primary or metastatic lesions. Exon 2 ofKRASand exon 15 ofBRAFwere analyzed by direct sequencing,PIK3CAwas evaluated by pyrosequencing and PTEN expression by immunohistochemistry.Results: BRAFandPIK3CAmutations were independently associated with worse PFS (p = 0.006 andp = 0.028, respectively) and OS (p = 0.008 andp = 0.029, respectively). No differences in clinical outcome were found between patients who were positive or negative for PTEN expression. Conversely, patients negative forKRAS,BRAFandPIK3CAmutations were characterized by significantly better ORR, PFS and OS than patients with at least one of these mutations.Conclusions: BRAFandPIK3CAmutations would seem to be independent predictors of anti-EGFR therapy effectiveness and could be taken into consideration during treatment decision making.


  • Open Access

    Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study

    by Chiara Molinari, Michela Ballardini, Nazario Teodorani, Massimo Giannini, Wainer Zoli, Ermanno Emiliani, Enrico Lucci, Alessandro Passardi, Paola Rosetti, Luca Saragoni, et al.

    Background: Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies. Methods: Forty-eight candidates for neoadjuvant chemoradiotherapy were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade. Results: Both Hidden Markov Model and Smoothing approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number of genome changes mainly located on 2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-34, 16p13, 17p13-12 and 18q23 chromosomal regions. Conclusions: This exploratory study suggests that an in depth characterization of chromosomal alterations by aCGH would provide useful predictive information on response to neoadjuvant chemoradiotherapy and could help to optimize therapy in rectal cancer patients. The data discussed in this study are available on the NCBI Gene Expression Omnibus [GEO: GSE25885].


    • 15 June 2011
      • Vol. 58  (106) , 599-603

    GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer.

    by Carlo Milandri, Rolando Polico, Domenico Garcea, Alessando Passardi, Andrea Gardini, Antonino Romeo, Emanuela Scarpi, Paola Rosetti, Laura Ridolfi, Giuliano La Barba, et al.

    The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000 mg/m2 on day 1, and oxaliplatin (OX) 100 mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25 Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.


  • HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer

    by Annalisa Volpi, Oriana Nanni, Franca De Paola, Anna Maria Granato, Annita Mangia, Franco Monti, Francesco Schittulli, Mario De Lena, Emanuela Scarpi, Paola Rosetti, et al.

    Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [ 3 H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.